SOUTH SAN FRANCISCO, Calif., January 03, 2024 Switch Therapeutics today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).
Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities Review includes differentiated mechanisms of action including tumor-localized activation, avidity-driven selectivity and novel SWITCH-DARPin approach ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech com
Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities.
Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities
Werewolf Therapeutics, Inc. announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company?s lead clinical program, WTX-124x2101. This clinical.